Ultima Vez Modificado: 19 de enero del 2003
Conference Dates: June 21-24, 2003
Conference Location: Wyndham Franklin Plaza Hotel in Philadelphia
Sponsoring Group: Foundation for Melanoma Research
Conference Web Page URL: www.foundationformelanomaresearch.org
Topics Covered: Immunology, Epidemiology, Biology, Molecular Biology and Tumor Microenvironment.
Conference Objectives: To provide the community of melanoma researchers with a comprehensive overview of the current state of research.
Who Should Attend: Physicians, Medical Oncologists, Traslational Researchers, Basic Researchers
Conference Agenda: The congress will begin on Saturday evening, June 21st, 2003 with keynote addresses by two prominent members of basic and translational melanoma fields. On Sunday and Monday, June 22nd and 23rd there will be plenary sessions in the morning and afternoon, each followed by three concurrent sessions for more detailed discussions. The last day's program on Tuesday, June 24 will have the same format but is restricted to the morning. Poster sessions in the evenings/late afternoons of Sunday and Monday will provide all participants the opportunity to present their research. The 5 plenary sessions will have 5 speakers each in immunology, epidemiology, biology, molecular biology and the tumor microenvironment. The 13 concurrent sessions will cover research areas that are evenly divided among the different research topics. On Monday evening the Melanoma Research Society will be inaugurated. In future years it will be the main sponsor of research meetings.! The Second Melanoma Research Congress will be held in 2005.
Registration Information: Register online at www.foundationformelanomaresearch.org, by mail by writing to FMR, 3601 Spruce Street, Room 489, Philadelphia, PA 19104
Conference Fees: Physicians and Scientists before 4/11: $350 and Students: $200 After 4/11 the fee schedule changes.
Continuing Education: No
Aug 24, 2012 - In the first-line treatment of metastatic melanoma, interleukin-21 shows an overall response rate of 22.5 percent and warrants further study, according to research published online Aug. 20 in the Journal of Clinical Oncology.
May 21, 2010
Oct 26, 2011
Jul 26, 2012